Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELISPOT-guided CMV prevention after heart transplantation
2019-002233-11Phase 4Active
- Sponsor
- José González-Costello
- Start
- Dec 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of valganciclovir and ganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by José González-Costello. Primary endpoint: Incidence of CMV infection during the first year after heart transplantation. Started Dec 2019; status: active.
02
Drugs
valganciclovirganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2019-002233-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002233-11.